Observation Study on the Efficacy of Yiqi Gubiao Pill in the Treatment of Chronic Obstructive Pulmonary Disease Secondary to Active Pulmonary Tuberculosis
Observation Study on the Efficacy of Yiqi Gubiao Pill in the Treatment of Chronic Obstructive Pulmonary Disease Secondary to Active Pulmonary Tuberculosis: A Double-Blind Randomized Controlled Trial Protocol
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Jin Dai, Attending Physician
- Phone Number: 0316-17590826125
- Email: daijintcm@163.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
-
Patients who meet the following criteria will be included:
- Age 40-75 years old;
- Meet the Western medical diagnostic criteria and typing standards for active PTB;
- Patients who have not taken steroids, anti-tuberculosis drugs, or other immunosuppressants and have not undergone desensitization treatment within one month.
- Have understood the treatment methods and voluntarily signed the informed consent form.
Exclusion Criteria:
-
Patients who meet any of the following criteria will be excluded:
- Patients with pneumothorax, pleural effusion, lung cancer and other serious lung diseases;
- Patients with severe cardiovascular and cerebrovascular, hepatorenal and hematopoietic diseases;
- mentally ill;
- Patients with tumors;
- Congenital or acquired immunodeficiency.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Yiqi Gubiao pill
|
Take 10 pills orally each time, three times a day, after meals, for a continuous period of 12 weeks.
Receiving basic treatment: standardized quadruple anti-tuberculosis therapy is administered, with Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide used for the first 2 months, followed by Rifampicin and Isoniazid for the next 4 months.
|
|
Placebo Comparator: Yiqi Gubiao Pill placebo
|
The placebo's appearance and content color are similar to that of Yiqi Gubiao Pill, with the main ingredients being starch and caramel.
Take 10 pills orally each time, three times a day, after meals, for a continuous period of 12 weeks.
Receiving basic treatment: standardized quadruple anti-tuberculosis therapy is administered, with Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide used for the first 2 months, followed by Rifampicin and Isoniazid for the next 4 months.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Forced Vital Capacity
Time Frame: up to 4 weeks
|
Forced Vital Capacity (FVC) refers to the volume of air exhaled as quickly and forcefully as possible after taking the maximum inhalation.
|
up to 4 weeks
|
|
the percentage of FVC predicted
Time Frame: up to 4 weeks
|
The volume of air exhaled rapidly within one second after inhaling to the total lung capacity.
Normal values are 70-85%, mild is less than 80% of the predicted value; moderate is less than 70% of the predicted value; moderately severe is less than 60% of the predicted value; severe is less than 50% of the predicted value.
|
up to 4 weeks
|
|
the ratio of FEV1 to FVC
Time Frame: up to 4 weeks
|
The ratio of FEV1 to FVC should be above 70%.
If the ratio is below 70%, it may indicate the presence of chronic obstructive pulmonary disease (COPD).
|
up to 4 weeks
|
|
COPD Assessment Test (CAT) score
Time Frame: up to 4 weeks
|
The CAT score questionnaire is primarily used to assess the health status and impact on daily life of patients with chronic obstructive pulmonary disease (COPD).
It quantifies the degree of health impairment in COPD patients by asking questions related to symptoms, activity ability, mental state, and social impact based on the patients' self-reports.
The total score of the CAT questionnaire ranges from 0 to 40, with higher scores indicating poorer health status and lower quality of life for the patients.
|
up to 4 weeks
|
|
modified Medical Research Council (mMRC) score
Time Frame: up to 4 weeks
|
The mMRC is only used for the assessment of dyspnea and is often applied in conjunction with the CAT score.
An mMRC score of 2 or above is the threshold for distinguishing "mild dyspnea" from "severe dyspnea."
|
up to 4 weeks
|
|
Baseline Dyspnea Index (BDI) score
Time Frame: up to 4 weeks
|
It measures activity-related dyspnea from three dimensions: degree of functional impairment, amount of activity, and effort required to complete activities.
Each dimension is graded on a 5-level scale, with scores ranging from 0 to 4, indicating increasing severity.
The total score ranges from 0 to 12.
|
up to 4 weeks
|
|
Transition Dyspnea Index (TDI) score
Time Frame: up to 4 weeks
|
The TDI should be used in conjunction with the BDI to measure the extent of change in prognostic functional impairment, activity level, and effort required to complete activities.
The TDI scores each dimension on a scale from significantly worse (-3) to significantly better (+3), with a total score ranging from -9 to +9.
|
up to 4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Traditional Chinese Medicine (TCM) symptom score
Time Frame: up to 4 weeks
|
The main symptoms and secondary symptoms are graded from mild to severe into 4 levels.
The main symptoms are scored 0, 2, 4, 6 points respectively, and the secondary symptoms are scored 0, 1, 2, 3 points respectively.
The tongue and pulse are not scored.
The sum of the scores for all symptoms is the total TCM symptom score.
|
up to 4 weeks
|
|
alanine aminotransferase
Time Frame: up to 4 weeks
|
The reference range is 0-40 U/L.
|
up to 4 weeks
|
|
aspartate aminotransferase
Time Frame: up to 4 weeks
|
The reference range is 0-40 U/L.
|
up to 4 weeks
|
|
urea nitrogen
Time Frame: up to 4 weeks
|
Reference range value 3.2-7.1 mmol/L
|
up to 4 weeks
|
|
serum creatinine
Time Frame: up to 4 weeks
|
Reference range value: Males 53-106 μmol/L, Females 44-97 μmol/L
|
up to 4 weeks
|
|
uric acid
Time Frame: up to 4 weeks
|
Normal serum uric acid values: for adult males, 149-416 μmol/L; for adult females, 89-357 μmol/L.
|
up to 4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Chronic Disease
- Disease Attributes
- Respiratory Tract Infections
- Infections
- Respiratory Tract Diseases
- Gram-Positive Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Actinomycetales Infections
- Mycobacterium Infections
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Tuberculosis
- Tuberculosis, Pulmonary
Other Study ID Numbers
Other Study ID Numbers
- 2021D01C215
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.